|
|
| | | What you need to know about the coronavirus today |
| |
Chinese vaccine candidate shows promise in animal tests Animal tests of a potential COVID-19 vaccine being developed by Chinese researchers show it triggers an immune response against the coronavirus, offering some promise as it goes into early-stage human trials, according to a peer-reviewed study. ARCoV is a messenger RNA vaccine which uses technology similar to candidates being developed by Moderna and BioNtech and Pfizer. It is the second potential COVID-19 vaccine that China’s military-backed research unit has moved into clinical trials. Results of trials of ARCoV in mice and monkeys, published in the peer-reviewed medical journal Cell on Thursday, show both single and two-dose inoculations induced strong antibody and T-cell responses against several COVID-19-causing virus strains.
Lonza cites Trump support on Moderna vaccine project Swiss drugmaker Lonza sees no delays for its project to make Moderna’s COVID-19 vaccine candidate and has “strong support” from President Trump to get the necessary manufacturing equipment, its chairman said. Chairman Albert Baehny had earlier raised concerns that hiring qualified staff and finding gear like bioreactors on short notice could snarl aggressive goals to begin commercial manufacturing of vaccine ingredients for Moderna. Lonza is readying production of smaller batches this month for Moderna’s mRNA vaccine trials in 30,000 people.
India reports record 49,000 new coronavirus cases India reported over 49,000 fresh cases of the novel coronavirus with 740 new deaths on Friday, marking the biggest daily surge in cases even as officials in some states complained of shortages of vital drugs for those hospitalized. As the number of cases neared 1.3 million in India, local authorities scrambled to procure generic versions of remdesivir, the drug that has shown promise in clinical trials in treating severely-ill patients with COVID-19, the disease caused by the coronavirus.
Britain’s home testing dogged by delays When Rachel Holdsworth developed a fever, she found her nearest coronavirus testing centre was an hour away by foot. So she ordered a home test kit through the National Health Service. It didn’t arrive for two days. Her sample wasn’t delivered to a laboratory until two days after that. By the time she received the test result in a text message – it was negative – five days had passed. To expand badly needed COVID-19 testing, the government has bet heavily on home testing, a strategy other countries severely affected by the virus haven’t tried. Home tests are now offered to anyone who exhibits symptoms. | |
| |
| |
Reuters reporters and editors around the world are investigating the response to the coronavirus pandemic.
We need your help to tell these stories. Our news organization wants to capture the full scope of what’s happening and how we got here by drawing on a wide variety of sources. Here’s a look at our coverage.
Are you a government employee or contractor involved in coronavirus testing or the wider public health response? Are you a doctor, nurse or health worker caring for patients? Have you worked on similar outbreaks in the past? Has the disease known as COVID-19 personally affected you or your family? Are you aware of new problems that are about to emerge, such as critical supply shortages?
We need your tips, firsthand accounts, relevant documents or expert knowledge. Please contact us at coronavirus@reuters.com.
We prefer tips from named sources, but if you’d rather remain anonymous, you can submit a confidential news tip. Here’s how. | |
|
| |
|
|
|
| | Follow the money |
European planemaker Airbus made what it described as a final step aimed at halting a transatlantic trade war over billions of dollars of aircraft subsidies. Airbus said it had agreed to pay higher interest rates on government loans it received from France and Spain to help develop its A350 jet, which entered service in 2015. 3 min read | |
The number of outright failures of U.S. small businesses in the first months of the coronavirus pandemic was comparatively modest, but the months ahead look far grimmer as cash balances dwindle, federal help expires, and the disease surges back. 6 min read | |
Malaysia said Goldman Sachs has agreed to a $3.9 billion settlement with the government over the multi-billion dollar 1MDB scandal. The deal includes a $2.5 billion cash payout by Goldman and a guarantee by the bank to return at least $1.4 billion in assets linked to 1MDB bonds, Malaysia’s finance ministry said in a statement. 1 min read | |
Lawyers for Meng Wanzhou, the chief financial officer of Huawei, have applied to a Canadian court seeking stays in the proceedings for her extradition to the United States, documents showed. 3 min read | |
More than a thousand Twitter employees and contractors as of earlier this year had access to internal tools that could change user account settings and hand control to others, two former employees said, making it hard to defend against the hacking that occurred last week. 6 min read | |
|
| |
|
|
| | Top Stories on Reuters TV |
|
| |
|
|
|